227 related articles for article (PubMed ID: 33963928)
1. Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae.
Balkan II; Alkan M; Aygün G; Kuşkucu M; Ankaralı H; Karagöz A; Şen S; Arsu HY; Biçer M; Kaya SY; Karaali R; Mete B; Saltoğlu N; Tabak F
Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2161-2170. PubMed ID: 33963928
[TBL] [Abstract][Full Text] [Related]
2. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality.
Rojas LJ; Salim M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Marshall S; Rudin SD; Domitrovic TN; Hujer AM; Hujer KM; Doi Y; Kaye KS; Evans S; Fowler VG; Bonomo RA; van Duin D;
Clin Infect Dis; 2017 Mar; 64(6):711-718. PubMed ID: 27940944
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for the Development of Colistin Resistance during Colistin Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
Huang PH; Chen WY; Chou SH; Wang FD; Lin YT
Microbiol Spectr; 2022 Jun; 10(3):e0038122. PubMed ID: 35652641
[TBL] [Abstract][Full Text] [Related]
4. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
5. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae.
Gonzalez-Padilla M; Torre-Cisneros J; Rivera-Espinar F; Pontes-Moreno A; López-Cerero L; Pascual A; Natera C; Rodríguez M; Salcedo I; Rodríguez-López F; Rivero A; Rodríguez-Baño J
J Antimicrob Chemother; 2015 Mar; 70(3):905-13. PubMed ID: 25344809
[TBL] [Abstract][Full Text] [Related]
6. A challenging case of carbapenem resistant Klebsiella pneumoniae-related pyogenic liver abscess with capsular polysaccharide hyperproduction: a case report.
Sohrabi M; Pirbonyeh N; Alizade Naini M; Rasekhi A; Ayoub A; Hashemizadeh Z; Shahcheraghi F
BMC Infect Dis; 2024 Apr; 24(1):433. PubMed ID: 38654215
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae.
Huang PH; Cheng YH; Chen WY; Juan CH; Chou SH; Wang JT; Chuang C; Wang FD; Lin YT
Int J Antimicrob Agents; 2021 Jun; 57(6):106342. PubMed ID: 33864932
[TBL] [Abstract][Full Text] [Related]
9. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
10. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Vieceli T; Henrique LR; Rech TH; Zavascki AP
J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
[TBL] [Abstract][Full Text] [Related]
11. Could Frequent Carbapenem Use Be a Risk Factor for Colistin Resistance?
Gundogdu A; Ulu-Kilic A; Kilic H; Ozhan E; Altun D; Cakir O; Alp E
Microb Drug Resist; 2018; 24(6):774-781. PubMed ID: 29028174
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
[TBL] [Abstract][Full Text] [Related]
13. [Klebsiella pneumoniae Infections in the Intensive Care Unit: Risk Factors Related to Carbapenem Resistance and Patient Mortality].
Büyüktuna SA; Hasbek M; Çelik C; Ünlüsavuran M; Avcı O; Baltacı S; Fırtına Topcu K; Elaldı N
Mikrobiyol Bul; 2020 Jul; 54(3):378-391. PubMed ID: 32755515
[TBL] [Abstract][Full Text] [Related]
14. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience.
Veeraraghavan B; Shankar C; Karunasree S; Kumari S; Ravi R; Ralph R
Pathog Glob Health; 2017 Jul; 111(5):240-246. PubMed ID: 28670975
[TBL] [Abstract][Full Text] [Related]
15. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
16. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections.
Ben-David D; Kordevani R; Keller N; Tal I; Marzel A; Gal-Mor O; Maor Y; Rahav G
Clin Microbiol Infect; 2012 Jan; 18(1):54-60. PubMed ID: 21722257
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Demirlenk YM; Gücer LS; Uçku D; Tanrıöver C; Akyol M; Kalay Z; Barçın E; Akcan RE; Can F; Gönen M; Ergönül Ö
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):761-769. PubMed ID: 35303195
[TBL] [Abstract][Full Text] [Related]
19. Healthcare-associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections: Risk factors, mortality, and antimicrobial susceptibility, 2017-2019.
Hsu JY; Chuang YC; Wang JT; Chen YC; Hsieh SM
J Formos Med Assoc; 2021 Nov; 120(11):1994-2002. PubMed ID: 33962811
[TBL] [Abstract][Full Text] [Related]
20. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
